筹划重大资产重组！成都先导拟受让海纳医药65%股权

Group 1 - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. is planning a major asset restructuring to acquire approximately 65% of the shares of Nanjing Haina Pharmaceutical Technology Co., Ltd. in cash, which will make Chengdu Xian Dao the controlling shareholder of Haina Pharmaceutical [1] - Haina Pharmaceutical, established in 2001 with a registered capital of approximately 95.22 million, has developed into a comprehensive pharmaceutical R&D group covering new drug discovery, pharmaceutical research, process development, clinical research, and drug production [1] - Chengdu Xian Dao focuses on the discovery and optimization of small molecules and nucleic acid new drugs, leveraging four core technology platforms to create an internationally leading R&D system [2] Group 2 - The acquisition is viewed as a strategic move to extend Chengdu Xian Dao's operations downstream, enhancing its capabilities in the drug development process [2] - If the transaction is completed, it is expected to lead to effective resource integration and synergy, promoting rapid business development for Chengdu Xian Dao [2] - Chengdu Xian Dao reported a total revenue of approximately 427 million for 2024, a year-on-year increase of 14.99%, and a net profit of approximately 50.94 million, up 25.09% year-on-year [2]